BHI Sales by Brand
| 6 months to 30th September 2004 |
Sales £M |
Growth % |
|---|---|---|
| Nurofen | 72 | +7.1% |
| Clearasil | 42 | +2.5% |
| Strepsils | 39 | +6.7% |
| Dermo-cosmetics | 22 | -9.5% |
| Other | 69 | +7.9% |
| Total | 244 | +4.8% |
- Sales growth shown for local currency
Notes
Nurofen was again the best performing core brand, up 7%. It showed particularly strong growth in Australia, due to the switch to general sales list, and in Central Europe and Russia.
Growth in Clearasil was more modest, up 2.5%. Performance was hit by distributor issues in Japan where sales were down 50%. Excluding Japan, growth was 7%. Sales in the US were up 3.4%, with gains in both market share and underlying consumption.
Strepsils grew almost 7% with good performance in continental Europe and Asia.
